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Purpose: The facilitation capability of neuronal lineages derived from transplanted 
stem cells is essential to improve the low efficacy of neuronal differentiation in stem 
cell therapy in vivo. Neurogenin 1 (Ngn1), a basic helix-loop-helix factor, has been 
used as an activator of neuronal differentiation. In this study, we monitored the in 
vivo activation of neuronal differentiation by Ngn1 in neuronal precursor cells using 
neuron-specific promoter-based optical reporters.  
Methods: The NeuroD promoter coupled with the firefly luciferase reporter system 
(pNeuroD-Fluc) was used to monitor differentiation in F11 neuronal precursor cells. 
In vitro luciferase activity was measured and normalized by protein content. The in 
vivo-jetPEITM system was used for in vivo transgene delivery. The IVIS 100 
imaging system was used to monitor in vivo luciferase activity. 
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Results: The Ngn1-induced neuronal differentiation of F11 cells generated neurite 
outgrowth within 2 days of Ngn1 induction. Immunofluorescence staining 
demonstrated that early and late neuronal marker expression (βIII-tubulin, NeuroD, 
MAP2, NF-M, and NeuN) was significantly increased at 3 days after treatment with 
Ngn1. When Ngn1 and the pNeuroD-Fluc vector were co-transfected into F11 cells, 
we observed an approximately 11-fold increase in the luciferase signal. An in vivo 
study showed that bioluminescence signals were gradually increased in Ngn1-treated 
F11 cells until 3 days.  
Conclusions: In this study, we examined the in vivo tracking of neuronal 
differentiation induced by Ngn1 using an optical reporter system. This reporter 
system could be used effectively to monitor the activation efficiency of neuronal 
differentiation in grafted stem cells treated with Ngn1 for stem cell therapy. 
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The use of multipotent stem cells to restore damaged tissue in terms of stem 
cell therapy has been well documented. With their effective differentiation potential, 
neural stem cells (NSCs) or neural precursor cells can provide the ideal cell source for 
the treatment of neurodegenerative diseases of the brain. Transplantation of NSCs or 
neuronal precursor cells has the potential to restore the functional deficits associated 
with injury to the central nervous system [1]. Cell replacement and gene transfer to 
the injured brain have provided an ideal source of new therapeutic strategies for 
human neurodegenerative diseases including Parkinson’s disease, Huntington’s 
disease, and Alzheimer’s disease [1–6]. Indeed, intravenously transplanted human 
NSCs effectively migrated to the damaged region, differentiated into neurons and 
astrocytes, and ultimately induced a functional improvement in rats with focal 
cerebral ischemia [7–8]. Although stem cell-based research has been studied 
intensively, the low efficiency of differentiation into functioning neuronal cells has 
hampered functional improvements. Therefore, the development of critical factors to 
promote neuronal differentiation by modulating endogenous neuron-specific genes is 
necessary for effective stem cell-based therapy.  
Neurogenin 1 (Ngn1) is a basic helix-loop-helix (bHLH) transcription factor 
that is expressed in early neuronal progenitor cells during the development of the 
nervous system [9]. The overexpression of Ngn1 increases the number of neuronal 
cells in Xenopus embryos and in uncommitted pluripotent stem cells, e.g., embryonic 
carcinoma P19 cells, by the activation of downstream proneural bHLH transcription 
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factors, including NeuroD [10]. Ngn1 suppresses gliogenesis by sequestering CREB 
binding protein/p300 and Smad1 away from the signal complexes that are required for 
the expression of glial fibrillary acidic protein [9, 11]. Kim et al. reported that the 
overproduction of Ngn1 alone is sufficient to induce neurite outgrowth in F11 
neuronal precursor or mouse embryonal carcinoma P19 cells [10, 12]. F11 cells are a 
hybrid cell line between neuroblastoma N18TG2 and dorsal root ganglionic neurons. 
These cells have unique characteristics in that they can be differentiated into neuron-
like cells in the presence of cAMP and express various neuron-specific markers, 
including specific receptors for prostaglandin and N- and L-type voltage-dependent 
Ca2+ channels, suggesting that F11 cells are similar to neuronal precursor cells [13].  
An in vivo molecular imaging approach has emerged as a powerful technique 
to identify the in vivo characteristics of implanted cells. To assess the location and 
proliferation or differentiation of the grafted stem cells in vivo, molecular markers, 
e.g., β-galactosidase, alkaline phosphatase, or green fluorescent protein, are used for 
immunochemical detection or in situ hybridization, particularly to prove the 
localization or neuronal commitment of grafted cells [14–20]. However, this method 
is too invasive and requires a tissue biopsy, which is difficult to repeat in the same 
animal. The application of in vivo noninvasive and quantifiable methods to estimate 
the differentiation potential of stem cells in vivo could confer important information 
at the level of small animals. Previously, we demonstrated a new noninvasive method 
to evaluate neuronal differentiation in vivo and in vitro by examining the expression 
of a reporter gene under the transcriptional control of a neuron-specific promoter in 
F11 cells [14]. In the present study, we monitored the activation process of neuronal 
differentiation induced by the neuronal activator Ngn1 using optical imaging reporters 
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II. MATERIALS AND METHODS 
 
Plasmid DNA vectors 
 
The plasmid vector containing full-length mouse Ngn1 cDNA was provided by 
Professor Haeyoung Suh-Kim, Ajou University. Full-length Ngn1 cDNA (GeneBank 
U63841) was obtained by polymerase chain reaction (PCR) using the 
oligonucleotides TGC AAG ATG CCT GCC CCT TT (forward) and GCC ATA GGT 
GAA GTC TTC TGA AGC CGA GGG ACT ACT G (reverse) and subcloned into the 
pCR2.1-TOPO plasmid. The cDNA was inserted into the EcoR I site of 
pcDNA3.1/His (B) to yield pcDNA/His-Ngn1 [10]. pNeuroD(-2.2)-Fluc contained a 
firefly luciferase reporter gene under the control of 2.2 kb of the mouse NeuroD 
promoter. This reporter gene contains cis-elements for the tissue-specific expression 
of NeuroD in the nervous tissue and pancreatic islets [21]. 
 
Cell culture and transfection protocol 
 
F11 cells, rat dorsal root ganglion and mouse neuroblastoma hybrid cells, and 
HeLa cells (human cervical cancer cells) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco, 
Grand Island, NY), 10 U/ml penicillin, and 10 μg/ml streptomycin. The cells were 





cells in 6-well plates. The pNeuroD(-2.2)-Fluc reporter gene, pcDNA/His-Ngn1, and 
pcDNA3.1/His(B) were transfected into F11 cells using lipofectamine (Invitrogen, 
Carlsbad, CA) and diluted in OPTI-MEM medium (Gibco, Grand Island, NY). The 
transfected cells were incubated in DMEM supplemented with 0.5% FBS for 2 or 3 
days. 
 
Quantitative analysis of the expression of neuronal markers using 
quantitative reverse transcription-PCR  
 
Using Trizol (Invitrogen, Grand Island, NY), total RNA was isolated during 
the neuronal differentiation of F11 cells. Total RNA (1 μg/ml) was reverse transcribed 
using reverse transcriptase (Invitrogen, Carlsbad, CA) for quantitative reverse 
transcription-PCR (qRT-PCR) analysis. qRT-PCR was performed using neuron-
specific primers. The PCRs were performed in triplicate using an ABI
®
 7500 (Applied 
Biosystems
TM
, Carlsbad, CA) with EvaGreen qPCR Mastermix (abm™, Richmond, 
BC). The reactions were incubated at 50°C for 2 min, 95°C for 10 min, and 40 cycles 
of 95°C for 15 s and 60°C for 1 min. To normalize the experimental samples, β-actin 




Mock-treated and Ngn1-treated F11 cells were seeded on cover slips in 6-well 
plate. After discarding the medium and rinsing with phosphate-buffered saline (PBS), 
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the cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at room 
temperature. Afterward, the cells were washed 3 times with PBS and incubated in 0.5% 
H2O2 in MeOH for 5 min at 20°C. After washing with PBS 3 times, the cells were 
treated with 0.5% Triton X-100 in PBS for 5 min at 4°C. The samples were rinsed 3 
times with PBS and non-specific binding sites were blocked with 1% normal horse 
serum in PBS for 1 h at room temperature. Anti-Tuj-1 (1:1300 dilution; Cell 
Signaling, Danvers, MA), anti-NeuroD (1:500 dilution; Abcam, Cambridge, FL), anti-
MAP2 (1:1000 dilution; Sigma, Saint Louis, MO), anti-NF-M (1:2000 dilution; 
Sigma, Saint Louis, MO), and anti-NeuN (1:100 dilution; MILLIPORE, Temecula, 
CA) antibodies were diluted in PBS and incubated with the samples at 4°C overnight. 
Alexa Fluor 488-conjugated anti-mouse and anti-rabbit secondary antibodies 
(Invitrogen, Grand Island, NY) were used to visualize the antibody reactions. Nuclei 
were counterstained with 4'-6-diamidino-2-phenylindole (DAPI; Vector Laboratories, 
Inc., Burlingame, CA) and observed at 461 nm. Fluorescent images were acquired 
using a confocal laser scanning microscope (Carl Zeiss LSM 510; Carl Zeiss, Jena, 
Germany).  
 
Quantitative analysis of the expression of neural markers 
 
Confocal data were used for quantitative analysis using TissueFAXS2.0. Firstly, 
the field of view for the areas of interest was set after pre-scanning to identify tissue 
sections. The fluorescent signals from the areas of interest were detected using 
TissueFAXS2.0. TissueFAXS yields rapid high resolution images of tissue sections 
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for subsequent analysis. Quantitative analysis was performed using TissueQuest, the 
cell analysis software for fluorescent images. 
 
In vitro luciferase assay 
 
F11 and HeLa cells were washed with PBS and lysed using a lysis buffer 
(Promega, Madison, WI) at 48 h after transfection. The cell lysates were collected 
with a cell scraper and redistributed into a 96-well plate. The luciferase assay was 
carried out using a luciferase assay kit (Promega, Madison, WI). The bioluminescence 
intensity of each cell lysate was measured using a microplate luminometer (TR717; 
Applied Biosystems
TM
, Carlsbad, CA). Luciferase activity was normalized by protein 
content. 
 
In vivo bioluminescence imaging 
 
First, at 24 h after F11 cells were transfected with the pNeuroD-Fluc and pCMV-
Gluc vectors, they were detached by trypsinization and harvested in PBS. An injection 
volume of 100 μl containing 1.5 × 10
6 
cells mixed with in vivo-jetPEI
TM
-Mock or 
Ngn1 were injected subcutaneously (s.c.) into the right thigh of male BALB/c nude 
mice with in vivo-jetPEI
TM
-Ngn1 complexes and into the left thigh with in vivo-
jetPEI
TM
-Mock complexes. The mice were anesthetized with 10 μl zoletil-rumpun 
(2:1) solution, and 3 mg D-luciferin suspended in 100 μl PBS was injected 
intraperitoneally at 10 min before the acquisition of the bioluminescence images. 
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Whole-body images for Fluc activity were acquired after 10 min. The Gluc signal 
from the gaussia luciferase gene, which is under the control of the cytomegalovirus 
(CMV) promoter, was used for Fluc signal normalization. To acquire Gluc images, 12 
h after the Fluc images were taken, 5 μg coelenterazine substrate (Biotium, Hayward, 
CA) were injected directly into the implanted F11 cells of the subcutaneous region. 
The Gluc images were acquired at an acquisition time of 1 min. Then, the mice were 
placed in an IVIS-100 imager (Xenogen, Alameda, CA,). Bioluminescence images for 
Fluc activity were acquired for 1 and 3 min. The Fluc and Gluc signals were analyzed 
quantitatively by region of interest (ROI). 
 
In vivo bioluminescence imaging for orthotopic implantation 
 
For the in vivo imaging study of the brain, F11 cells transfected with the 
pNeuroD-Fluc vector in a T75 flask were harvested by trypsinization. The cells were 
spun, rinsed, and resuspended in 500 μl PBS. A CM-DiI cell-labeling solution was 
mixed directly with PBS (2 μl CM-DiI labeling solution per mL of solution). Then, 
the F11 cells were incubated with CM-DiI/PBS for 20 min at 37°C. We injected 
BALB/c nude mice (n = 6) stereotactically after CM-DiI cell-labeling with 4.5 × 10
5
 
cells in a total fluid volume of 5 μl PBS into the right striatum (coordinates: 
anteroposterior, 0.5; mediolateral, 1.5; dorsoventral, 2.0) with in vivo-jetPEI
TM
-Ngn1 
complexes or in vivo-jetPEI
TM
-Mock complexes. Quantitative ROI data from the 






Histology and immunohistochemistry  
 
The mice were sacrificed using CO2 at 3 days after cell transplantation. The F11 
cells that were injected s.c. into the thighs were removed and then post-fixed with 4% 
PFA. Post-fixation, the isolated F11 cells were embedded in paraffin and 4 μm-thick 
sections were prepared. The brains were removed surgically, embedded in OCT, and 
frozen on a bed of liquid nitrogen. Serial (10 μm thick) cryosections were prepared 
and some of the cryosections were stained with hematoxylin and eosin. For 
immunohistochemistry, the sections were blocked with 1% normal goat serum in PBS 
for 1 h at room temperature. The sections were then incubated with antibodies against 
Tuj-1 (1:100 dilution; Cell Signaling, Danvers, MA), NeuroD (1:500 dilution; Abcam, 
Cambridge, FL), MAP2 (1:100 dilution; Sigma, Saint Louis, MO), NF-M (1:2000 
dilution; Sigma, Saint Louis, MO), and NeuN (1:100 dilution; MILLIPORE, 
Temecula, CA) at 4°C overnight. The primary antibody reactions were visualized 
with Alexa Fluor 488-conjugated anti-mouse and anti-rabbit secondary antibodies 
(Invitrogen, Grand Island, NY). Fluorescent signals were detected using a confocal 




Data are displayed as means ± standard deviation (SD) and assessed using 






Induction of neurite outgrowth by overproduction of Ngn1 in F11 cells 
 
To confirm the potential ability of neurogenic Ngn1 to induce neuronal 
differentiation, F11 cells were treated with a Mock or Ngn1-containing plasmid 
vector for 1 or 3 days to promote neuronal differentiation. The Mock vector was the 
pcDNA3.1/His expression vector of Ngn1 that does not contain Ngn1 cDNA and was 
used as a negative control. F11 cells were transfected with the Ngn1 transgene under 
two different serum concentrations to determine the optimal condition to induce the 
activation of neuronal differentiation by Ngn1.  
Because the optimal condition for neural induction was reported to be 0.5% 
FBS [12], 0.5% and 10% FBS conditions were used. Mock- and Ngn1-transfected 
F11 cells (F11-Mock or F11-Ngn1 cells, respectively) were incubated for either 1 or 3 
days in 0.5% or 10% FBS. The round cell shape morphology was unchanged in F11-
Mock cells, indicating their undifferentiated state. In addition, there was no 
significant change of F11 cell morphology in the groups treated with Ngn1 or Mock 
in 10% FBS (data not shown) and Mock in 0.5% FBS (Fig. 1a, c). In contrast, a 
significant neurite outgrowth pattern was observed in F11-Ngn1 cells incubated in 
DMEM containing 0.5% FBS (Fig. 1b, d). The length of neurite outgrowth was also 
estimated quantitatively from differential interference contrast images of confocal 
analysis of F11-Mock and F11-Ngn1 cells in 0.5% FBS. The individual length of 
neurite outgrowth was measured using LSM Image Examiner and showed a distinct 
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pattern between F11-Mock and F11-Ngn1 cells (n = 20). Neurite outgrowth in F11-
Ngn1 cells was, on average, 16-fold longer than in F11-Mock cells (Fig. 1e). 
 
Mesurement of neuron-specific gene expression after neuronal activation 
by treatment of Ngn1  
 
To investigate the ability of Ngn1 to activate neuronal differentiation, we firstly 
examined changes in the mRNA expression levels of a variety of neuron-specific 
genes at each neuronal developmental stage, including early and late neuronal 
markers. The expression levels of the early neuronal marker Tuj-1 and the late 
neuronal genes NeuroD, MAP2, and NF-M were evaluated using real-time RT-PCR 
analysis. Because dramatic neurite outgrowth was induced by Ngn1 in 0.5% FBS, 
RNA was isolated from F11 cells that were maintained in DMEM containing 0.5% 
FBS after transfection with the Mock or Ngn1 expression plasmid vector. 
Quantitative analysis by real-time RT-PCR revealed increased expression levels of 
Tuj-1, NeuroD, MAP2, and NF-M, except for the neuronal nuclear antigen (NeuN), in 
F11-Ngn1 cells compared to F11-Mock cells (Fig. 2). An immunostaining assay was 
also conducted to confirm whether Ngn1 overproduction induces neuronal 
differentiation at the protein level. The highly specific expression of early and late 
neuronal markers, i.e., Tuj-1, NeuroD, MAP2, and NF-M, was found in the cytoplasm 
of F11-Ngn1 cells, whereas they were expressed at minimal levels in F11-Mock cells. 
In addition, the nuclear expression of Ngn1 was detected in F11-Ngn1 cells (Fig. 3). 
However, NeuN, a mature neuronal marker that is expressed in the final stage of 
20 
 
neuronal differentiation, was not expressed in F11-Ngn1 cells, indicating that these 
cells do not reflect the last stage of neuronal differentiation, at least in an in vitro 
environment.  
To examine the changes of neuron markers induced by Ngn1 more accurately, a 
TissueFAX imaging analyzer, which is a quantitatively analyzable imaging 
microscope, was used to acquire total fluorescence signals from whole cells on a 
slideglass. Consistent with the immunostaining results, the immature neuronal marker 
Tuj-1, mature neuronal marker NeuroD, and neuron-specific cytoskeletal protein NF-
M exhibited approximately 2.5-, 1.8-, and 5.6-fold increased expression levels, 
respectively (data not shown). In particular, the MAP2 marker showed the greatest 
increase in expression when the Ngn1 gene was overexpressed. These data were 
significantly correlated with the higher level of MAP2 expression in the cytoplasm of 
F11-Ngn1 cells, as measured by immunocytochemistry. These results indicate that 
Ngn1 overexpression alone in F11 cells is sufficient to induce neuronal cell fate with 
changes of neuronal markers as well as of neuron-specific phenotypes. 
   
Evaluation of the effect of Ngn1 using a neuronal promoter-driven 
reporter gene  
 
A recombinant plasmid DNA vector carrying the firefly luciferase gene regulated 
by the NeuroD promoter (pNeuroD-Fluc) was designed to examine the activation of 
neuronal differentiation by Ngn1. HeLa cells, which have non-neuronal 
characteristics, were chosen as a negative control to confirm whether the NeuroD 
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promoter is only influenced by the overproduction of Ngn1. F11 and HeLa cells were 
transiently transfected with Mock or Ngn1 and pNeuroD-Fluc as a reporter gene. F11 
cells co-transfected with both Ngn1 and pNeuroD-Fluc genes exhibited approximately 
11-fold higher luciferase activity than F11-Mock cells (Fig. 4a). In contrast, only 1.6-
fold higher luciferase signals were observed in HeLa cells overexpressing Ngn1 
compared to Mock-transfected HeLa cells. These results indicate that although the 
activation of the NeuroD promoter was, to a certain degree, affected by Ngn1 itself, 
the level of activation was very low. Thus, Ngn1 is critical for the activation of 
neuronal differentiation by its interaction with a variety of other neurogenic factors in 
F11 cells.   
 
In vivo bioluminescence imaging to analyze the effect of Ngn1 in a 
subcutaneously injected F11 cell implantation group 
 
To monitor the activation pattern of neuronal differentiation in vivo by the 
induction of Ngn1, 1.5 × 10
6
 F11 cells were collected in 100 μl PBS after transfection 
with the pNeuroD-Fluc vector. The gaussia luciferase gene driven by the CMV 
promoter (pCMV-Gluc) was also used as an internal control for in vivo normalization. 
As for the in vivo delivery of the transgene, we used the in vivo-jetPEI
TM
 system, 
which is an in vivo delivery reagent for efficient nucleic acid delivery in many species, 
including the mouse and rabbit.  
Firstly, to evaluate the efficiency of transgene delivery into F11 cells by in vivo-
jetPEI
TM
, a retroviral vector carrying the enhanced luciferase (effluc) gene was tested 
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in F11 cells. After the effluc vector was mixed with 20 μl in vivo-jetPEI
TM
 for 15 min, 
F11 cells were injected s.c. into the right thigh of male BALB/c nude mice with in 
vivo-jetPEI
TM
-effluc vector complexes. Bioluminescence signals in the injected region 
were detected at 24 and 48 h after injection (Fig. 4b). After pNeuroD-Fluc and 
pCMV-Gluc-transfected F11 cells mixed with in vivo-jetPEI
TM
-Ngn1 complexes or -
Mock complexes were injected into the thighs of nude mice, serial images were 
acquired using an in vivo optical imaging device. The F11-Ngn1 injected group (right 
thigh) showed higher luciferase intensity than the F11-Mock injected group at 2 and 3 
days after injection. In contrast, Gluc activity in the right thigh of the F11-Ngn1 group 
gradually decreased (Fig. 4c), possibly because the proliferation rates of the F11-
Ngn1 group might be reduced continuously due to the induction of neuronal 
differentiation by Ngn1. The ROI value was calculated by dividing the firefly 
luciferase activity of pNeuroD-Fluc by the gaussia luciferase signal of the pCMV-
Gluc vector in the F11-Ngn1 and F11-Mock groups. The ROI value for the Fluc/Gluc 
activity ratio indicated that the luciferase signal in the F11-Ngn1 group increased 
continuously compared to the F11-Mock group (Fig. 4d). These results demonstrated 
that the increased luciferase activity in the F11-Ngn1 group was due to the activation 
of neuronal differentiation by Ngn1 in the transplanted F11 cells. 
To verify the activation of in vivo neuronal differentiation of the grafted F11 cells 
by Ngn1, we performed immunohistochemistry analysis for Ngn1 and neuronal-
specific markers, i.e., Tuj-1, NeuroD, MAP2, NF-M, and NeuN. At 3 days after the in 
vivo bioluminescence images were acquired, the injected F11 cells were isolated from 
the subcutaneous region for the immunohistochemistry assay. The expression of most 
of the neuron-specific markers, including NeuroD, was increased dramatically in the 
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F11-Ngn1 implanted region. In contrast, under the same conditions, these neuron-
specific proteins were expressed at a minimal level in the F11-Mock implanted region. 
We also performed quantitative analysis of the immunohistochemistry assay using 
TissueFAXS2.0. TissueFAXS analysis showed the increased expression of the 
neuron-specific markers, including NeuroD, except for NeuN, in the F11-Ngn1 group 
(data not shown). Interestingly, consistent with the in vitro immunofluorescence 
staining results, no fluorescent signal for NeuN expression was found, even in the 
F11-Ngn1 group (Fig. 5). These results indicated that the s.c. implanted F11-Ngn1 
cells were successfully induced into a neuronal cell lineage, but not the final stage of 
neuronal differentiation. 
 
In vivo orthotopic implantation of F11 cells to examine the activation of 
neuronal differentiation in the brain  
 
To evaluate the possibility of inducing neuronal activation of the implanted cells 
in the brain, we performed the orthotopic injection of F11 cells transfected with 
pNeuroD-Fluc into the right striatum region of nude mice after mixing them with in 
vivo-jetPEI
TM
-Ngn1 or -Mock complexes. In addition, to track the injected F11 cells 
in the brain, they were stained with the fluorescent tracker DiI before they were 
transplanted into the brain. At 3 days after the cells were injected intracranially, we 
detected a significant difference in brain luciferase intensity between the F11-Ngn1 
and F11-Mock groups (Fig. 6a). Quantitative analysis of the bioluminescence signal 
ratio (each day/0 day ratio) revealed similar luciferase intensity between the F11-
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Ngn1 and F11-Mock implantation groups until 2 days after cell implantation. 
However, the luciferase intensity ratio was significantly increased at 3 days in the 
F11-Ngn1 group (Fig. 6b). In these results, a somewhat different pattern of luciferase 
signal was found between the groups implanted in the subcutaneous environment and 
those implanted in brain tissue.  
For the immunohistochemistry assay of brain tissue, brain tissue was also isolated 
at 3 days after the bioluminescence imaging was performed. Ngn1 was expressed only 
in the F11-Ngn1 group. The increased expression of the neuron-specific markers Tuj-
1, NeuroD, MAP2, and NF-M markers was found in the implanted F11-Ngn1 cells. 
The fluorescence signal for the neuronal markers was matched with the DiI 
fluorescence signal. Interestingly, compared with the results acquired from in vitro 
immunostaining and the in vivo subcutaneous injection study, the high expression of 
the late neuronal marker NeuN was detected in brain sections from the F11-Ngn1 
group (Fig. 7). This result indicated that the brain environment surrounding the 
implanted cells can induce a different neuronal differentiation capability compared to 
the subcutaneous regions of mice. 
Quantitative analysis by TissueFAXS2.0 for the expression of immature and 
mature neuron-specific markers also supported the activation of neuronal 
differentiation with more accurate analysis than the immunostaining data. Consistent 
with the immunostaining findings, the immature neuronal marker Tuj-1 and mature 
neuronal marker NeuroD showed an approximately 1.6- and 38-fold increase in their 
expression levels, respectively (data not shown). The expression of the neuron-
specific cytoskeletal protein NF-M was 3.2-fold higher than in the F11-Mock group. 
In particular, MAP2 was expressed at the highest levels out of all of the examined 
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neural markers. The TissueFAXS analysis data were consistent with the 
immunohistochemistry findings, indicating the increased expression of neuronal 




















FIGURE 1 Induction of neuronal differentiation by Ngn1 alone in F11 cells. To 
examine the ability of Ngn1 to activate neuronal differentiation, F11 cells were 
transfected with 1 μg Mock or Ngn1 plasmid vector. These transfected F11 cells were 
incubated in DMEM containing 0.5% FBS for 3 days. (a, c) Mock (0.5% FBS) and (b, 
d) Ngn1 (0.5% FBS). Phase contrast photomicrograph showing Ngn1-induced F11 
cells had neuron-like morphological neurite outgrowth features (b, d). (e) Quantitative 
analysis for the length of neurite outgrowth was performed in F11-Mock and F11-
Ngn1 cells. The average length of neurites extending from the cell body was 




















FIGURE 2 Neuronal marker expression of Mock or Ngn1 treated F11 cells. Real-
time RT-PCR was performed on total RNA extracted from F11 cells treated with 
Mock or Ngn1. In F11-Ngn1 cells, the expression of several neuron-specific markers 
including NeuroD was higher than in the F11-Mock cells at 48 h. β-actin was used as 









FIGURE 3 Expression level in neuron-related proteins by Ngn1. 
Immunofluorescence studies to examine neuron-related proteins were conducted in 
F11-Mock and F11-Ngn1 cells. Immunofluorescence staining revealed the increased 
expression levels of Ngn1 (red), Tuj-1 (green), NeuroD (red), MAP2 (green), and NF-
M (red) in F11-Ngn1 cells compared to F11-Mock cells. Nuclei were counterstained 






















FIGURE 4 Enhanced luciferase reporter activity in F11 cells treated with Ngn1. (a) 
HeLa and F11 cells were transiently transfected with Mock or Ngn1 and pNeuroD-
Fluc as a reporter gene. Ngn1 overproduction increased the luciferase reporter signals 
in pNeuroD-Fluc-transfected F11 cells. Slightly increased luciferase activity was 
observed in the F11-Ngn1 cells. The acquired values are represented as the average 
luciferase activity ratio ± SD that was normalized using the bicinchoninic acid assay. 
(b) After the plasmid vector containing enhanced luciferase (effluc) gene was mixed 
with in vivo-jetPEITM, F11 cells (5×10
5
) mixed with effluc plasmid-polymer 
complex were subcutaneously (s.c.) injected into the right thigh of nude mouse. After 
24 h, markedly higher bioluminescence intensity was observed in injection site of F11 
cells mixed with in vivo-jetPEITM -lucferase gene complexes. No bioluminescence 
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signal was detected in F11 cells only mixed with luciferase vector. Arrow indicates 
cell injection site. (c) At 24 h after F11 cells were transfected with the pNeuroD-Fluc 
and pCMV-Gluc vectors, 1.5 × 10
6 
cells were injected s.c. into the right thigh of nude 
mice with in vivo-jetPEI
TM
-Ngn1 complexes and into the left thigh with in vivo-
jetPEI
TM
-Mock complexes. A gaussia luciferase reporter vector was used for in vivo 
normalization. Bioluminescence images were acquired using an IVIS-100 optical 
imaging device from 0 to 3 days. (d) ROI analysis from the bioluminescence images 
was carried out for each cell-implanted region. The Fluc/Gluc activity ratio from the 





















FIGURE 5 In vivo neuronal differentiation of F11 cells injected s.c. into thighs at 3 
days after cell implantation. The implanted F11 cells were isolated from each thigh of 
the nude mice, and each sample was fixed with 4% PFA for paraffin slide sections. 
Immunohistochemistry analysis demonstrated the increased expression of the 
transcription factor Ngn1 (red), immature neuronal marker Tuj-1 (green), and mature 
neuronal markers NeuroD (red), MAP2 (green), NF-M (green), and NeuN (green) in 





















FIGURE 6 In vivo bioluminescence imaging of Ngn1-induced F11 cells injected 
orthotopically into the brain. (a) At 24 h after F11 cells were transfected with 
pNeuroD-Fluc, 4.5 × 10
5 
cells were injected stereotactically into the right striatum of 
nude mice with in vivo-jetPEI
TM
-Ngn1 complexes or in vivo-jetPEI
TM
-Mock 
complexes. Bioluminescence images were acquired from 0 to 3 days. The enhanced 
bioluminescence signals in the F11-Ngn1 cell implantation group were detected at 3 
days after implanting the cells into the brain. (b) ROI values are expressed as the ratio 
each day/0 day ratio. Significantly increased luciferase intensity was found in the 
F11-Ngn1 group mixed with in vivo-jetPEI
TM
-Ngn1 complexes at 3 days after cell 


















FIGURE 7 Ex vivo validation study for the activation pattern of neuronal 
differentiation in brains implanted with F11-Ngn1 cells. As soon as the brain tissue 
was isolated from nude mice at 3 days after cell transplantation, it was fixed with 4% 
formaldehyde. Neuron-specific antibodies to the transcription factor Ngn1, the marker 
for early differentiating neurons Tuj-1, and the mature neuronal markers NeuroD, 
MAP2, NF-M, and NeuN were used to analyze the degree of neuronal differentiation 
induced by Ngn1 in the brain. The expression of all of the markers is shown in green. 

















In vivo monitoring of the activation process of grafted stem cells into specific cell 
lineages by neuronal-inducing factors enables us to track the activation efficacy of 
neuronal differentiation in living subjects. Indeed, an in vivo differentiation imaging 
approach can provide useful information not only for the evaluation of differentiation 
efficacy for the development of novel differentiation-inducing factors but also a better 
understanding of the therapeutic mechanism in terms of stem cell-based therapy. 
Currently, stem cell replacement therapy has been recognized as a unique therapeutic 
approach to repair neurodegenerative disorders such as Parkinson’s disease [22, 23]. 
However, since the grafted stem cells show low efficiency for their differentiation 
into functioning neurons in vivo, the development of effective neuron-inducing factors 
is required to enhance its therapeutic efficacy. In this study, we used the neurogenic 
transcription factor Ngn1 that represses gliogenesis directly and activates 
neurogenesis simultaneously by promoting the expression of NeuroD, which may 
become an ideal candidate for facilitating the induction of neuronal differentiation [9]. 
In this study, we showed that Ngn1 activated neuronal differentiation using a 
validation study with a variety of neuron-specific markers in neuronal precursor F11 
cells. We also established an in vivo imaging system to track the activation process of 
the grafted cells into a neuronal lineage using optical luciferase regulated by a neuron-
specific promoter. Using this system, we observed the significant change of F11 cells 
to a neuronal phenotype from the overexpression of the Ngn1 gene alone and culture 
in a low percentage of FBS. The low concentration of FBS, which reduces cell growth, 
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is one of the critical factors that accelerate the neuronal differentiation of neuronal 
precursor cells. Neuronal gene expression profiling using real-time RT-PCR was 
investigated to confirm whether the morphological changes induced by Ngn1 were 
caused by the extreme stress of exogenous gene transfection. In this study, we found 
the enhanced expression of several neuron-specific genes including NeuroD in F11-
Ngn1 cells (Fig. 2).  
It is of interest that Ngn1 activated neuronal differentiation in the neuronal 
precursor cells within a short period of time. This result indicates that it is not 
necessary to use a virus-based construct for long-term transgene expression; indeed, 
virus-mediated transduction may cause insertional mutagenesis or unexpected side 
effects [24, 25]. Transient transfection techniques using plasmid DNA vectors are also 
problematic in that they do not show the long-term effect of the transgene due to their 
“dilution” when the cells start to undergo division. However, in this case, since the 
activation of neuronal differentiation by Ngn1 occurred in a short period of time, the 
use of a plasmid vector encoding Ngn1 in this study is suitable in terms of safety. 
Immunofluorescence staining results also supported the activation of neuronal 
differentiation by Ngn1, showing the enhanced expressions of late neuronal proteins 
as well as early neuronal markers. Especially, the expression levels of MAP2, which 
forms the neuronal cytoskeleton, were the most distinctive between Mock and Ngn1 
induction. We analyzed various neuron-specific markers related to different neuronal 
stages between the F11-Mock and F11-Ngn1 groups. In addition, more accurate 
neuronal differentiation analysis using quantitative measurements based on individual 
fluorescence was included in this study. From those results, we acquired concrete 
information for the extent of differentiation induced by Ngn1 according to neuronal 
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stage. Especially, the acceleration process into the neuronal lineage in vivo was 
monitored successfully in the mouse model via the orthotopic as well as subcutaneous 
injection of neuronal precursor cells.  
To deliver the transgene of interest into cells in vivo, an efficient in vivo gene 
delivery system is required. In this study, we utilized the cationic polyethyleneimine 
(PEI) polymer that has been widely used for gene delivery in vivo [26, 27]. In a 
previous study, there was no induction of major pro-inflammatory cytokines such as 
TNF-α, IL-6, and IL-12/IL-23 using in vivo-jetPEI
TM
 systemic delivery of DNA and 
siRNA in vivo compared to other lipophilic reagents. Therefore, we used the in vivo-
jetPEI
TM
 system for our in vivo systemic delivery experiments instead of 
lipofectamine. After the effective delivery of the transgene via in vivo-jetPEI
TM
 was 
verified using a general luciferase viral vector system, F11 cells carrying pNeuroD-
Fluc and pCMV-Gluc vectors were mixed with Ngn1 or Mock complexes within in 
vivo-jetPEI
TM 
and then injected into each thigh of nude mice. Acquired serial images 
indicated a higher luciferase signal over time in the right thigh injected with F11-
Ngn1 cells compared to the left thigh that was injected with F11-Mock cells. In 
contrast, the Gluc signal from F11 cells transfected with pCMV-Gluc was decreased 
gradually in the right thigh injected with F11-Ngn1 until 3 days. (Fig. 4c). These 
results indicated that the in vivo induction of Ngn1 effectively represents its 
functional action by differentiating the grafted cells into the neuronal lineage and, at 
the same time, proliferation of the grafted cells was reduced by Ngn1-mediated 
neuronal differentiation. In addition, these findings were supported by the results from 
the microscopically observed immunohistochemistry data.  
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The in vitro study revealed that the expression of the early neuronal marker Tuj-1 
and mature neuronal markers MAP2 and NeuroD were significantly enhanced in F11-
Ngn1 cells, but not in F11-Mock cells (Fig. 3). In addition, neuronal differentiation 
was activated in F11 cells isolated from the subcutaneous and brain injection sites and 
they expressed Tuj-1, NeuroD, MAP2, and NF-M (Figs. 5,7). In contrast, NeuN, 
which is a late neuronal marker, was not expressed even after Ngn1 induction in the 
subcutaneous area or in vitro. However, compared to the above results, F11-Ngn1 
cells in the brain showed significantly increased NeuN expression. This result 
demonstrated that the injected F11-Ngn1 cells in the brain environment, which 
contains various neuronal or glial cell populations, may be affected by various factors 
secreted from host neuronal or glial cells, and allow for the progression of neuronal 
differentiation.  
In the optical imaging analysis of the brain, the in vivo normalization of the 
implanted F11 cells using gaussia luciferase expression is inaccessible because 
coelenterazine, which is the substrate for gaussia luciferase, cannot penetrate the 
blood-brain barrier. Thus, the development of a novel luciferase substrate that is 
capable of crossing the blood-brain barrier, which is similar to D-luciferin, is 
necessary for in vivo optical imaging in the brain. 
The neuron-specific reporter imaging technique offers powerful information to 
track the time course of neuronal differentiation using a noninvasive approach. Our 
approach regarding in vivo imaging for assessing the activation of neuronal 
differentiation by a neuron-inducing gene can represent a variety of applicable aspects 
for the therapeutic purpose. The in vivo efficiency of the extent of neuronal 
differentiation of grafted cells can be detected easily. In addition, this monitoring 
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system can provide useful knowledge to determine the capability of candidate Ngn1-
like neuronal-inducing factors to promote neuronal differentiation in vivo. Moreover, 
in terms of the enhancement of therapeutic efficacy in gene-based therapy, an in vivo 
imaging strategy to track the activation of neuronal differentiation induced by a 
neuronal activator can help to understand the therapeutic mechanisms underlying 
findings from behavior analysis for functional improvement. We expect that the 
ability to monitor the activation of neuronal differentiation by Ngn1 can be helpful to 
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목적: 생채 내에 이식된 줄기 세포는 신경세포로의 분화 효율이 매우 낮기 
때문에 이를 높이기 위해서는 신경세포로의 분화촉진을 유도 하는 유전자
가 필요 하다. 뉴로제닌 1은 신경 줄기 세포 및 신경 전구 세포에서 효과
적으로 신경세포 분화 활성을 나타내게 하는 전사 인자이다.  
본 연구에서는 신경세포 특이적인 프로모터를 가진 광학 리포터 유전자를 
이용하여 신경 전구 세포에서 뉴로제닌 1에 의한 신경세포로의 분화 활성
을 생체 내에서 모니터링 하고자 하였다. 
연구방법: 신경세포 특이적인 NeuroD 프로모터의 조절을 받아 firefly 
luciferase 리포터 유전자의 발현이 일어나도록 재조합 된 플라스미드 벡터 
(pNeuroD-Fluc) 를 이용하여 신경전구 세포인 F11 세포에서 일어나는 신경
세포 분화 활성을 모니터링 하였다. 뉴로제닌 1에 의해 유도된 신경세포의 
신경세포 특이적인 성질을 확인하기 위해 면역 염색을 실시하여 신경세포 
특이적인 마커들을 확인하였으며 마커 발현의 정량적인 분석을 위해 
TissueFAXs 분석을 추가적으로 진행하였다. 생체 내 pNeuroD-Fluc 의 광학 
시그널의 보정을 위해서 cytomegalovirus (CMV) 프로모터 조절을 받는 
gaussia luciferase 리포터 유전자 (CMV-Gluc) 를 사용하였다, 생체 내 유전자 
전달 시스템으로는 생체 내 jetPEITM 을 사용하였다. 
결과: 뉴로제닌 1이 처리 된 후 2 일 안에 신경전구 세포인 F11 세포에서
는 신경돌기가 뻣어 나오는 것을 관찰 할 수 가있다. 면역염색을 통해 뉴
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로 제닌 1이 처리된 그룹에서 신경세포 분화 초기 마커인 βIII-tubulin (Tuj-1) 
과 성숙한 신경세포에서 발현하는 NeuroD, MAP2 그리고 NF-M 의 발현이 
유의하게 증가 하는 것을 확인 할 수 있었다. 신경 전구 세포인 F11 세포
에 pNeuroD-Fluc 리포터 유전자와 뉴로제닌 1 혹은 Mock 벡터를 처리 하
였을 때 뉴로제닌 1이 처리 된 그룹에서는 Mock 이 처리 된 그룹에 비해 
광학 시그널이 11배 정도 증가 하는 것을 확인 할 수가 있었다. 또한 생체 
적합성 in vivo PEI를 이용하여 생체 내에 뉴로제닌 1 유전자를 전달하여 신
경세포 분화 활성을 관찰 하였을 때 pNeuroD-Fluc 와 pCMV-Gluc 가 동시
에 처리된 F11 세포에 뉴로제닌 1을 처리한 그룹이 Mock 벡터가 처리된 
그룹에 비해 3일째 까지 발광 시그널이 점차 증가 하는 것을 확인 할 수 
있었다. 그리고, 마우스 뇌에 F11 세포를 이식한 후 뉴로제닌 1을 유도 시
켰을 때 이식 3일 후 Mock 벡터가 처리된 그룹에 비해 뉴로제닌 1이 처리
된 그룹에서 광학 시그널이 유의하게 증가하는 것을 생체 내에서 영상화 
할 수 있었다. 
결론: 신경 전구세포에서 신경세포 특이적 광학 리포터 유전자를 이용하여 
뉴로제닌 1에 의한 신경세포 분화 활성을 생체 내에서 실시간 영상으로 추
적할 수 있음을 확인하였다. 이런 신경세포 분화 활성을 모니터링 하는 리
포터 유전자 이미징 시스템은 줄기세포 치료 시 신경세포 분화 유도 활성
제인 뉴로제닌 1에 의해 이식된 줄기 세포가 신경세포 분화 효율을 모니터
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